Journal
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
Volume 2, Issue 3, Pages 175-191Publisher
ELSEVIER
DOI: 10.1016/S1572-1000(05)00097-9
Keywords
Methylene blue; PDT; Photodynamic therapy; Apoptosis; Singlet oxygen; ROS; Cancer; Melanoma; Kaposi's sarcoma; Onychomicosis
Categories
Funding
- FAPESP
- CAPES
- CNPq
Ask authors/readers for more resources
Methylene blue (MB) is a molecule that has been playing important roles in microbiology and pharmacology for some time. It has been widely used to stain living organisms, to treat methemoglobinemia, and lately it has been considered as a drug for photodynamic therapy (PDT). In this review, we start from the fundamental photophysical, photochemical and photobiological characteristics of this molecule and evolved to show in vitro and in vivo applications related to PDT. The clinical cases shown include treatments of basal cell carcinoma, Kaposi's Sarcoma, melanoma, virus and fungal infections. We concluded that used together with a recently developed continuous light source (RL50 (R)), MB has the potential to treat a variety of cancerous and non-cancerous diseases, with low toxicity and no side effects. (C) 2005 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available